Back to search

Article

Vildagliptin modulates the microbiota and induces an immunometabolic neuroprotective profile in type 2 diabetes

2025-05-30

Abstract excerpt

<title>Abstract</title> <p>Dipeptidyl peptidase 4 <bold>(</bold>DPP-4) inhibitors (DPP-4i) are widely used to treat Type 2 diabetes (T2D) and are known for their cardiovascular and renal safety profiles. Systematic reviews have also shown that DPP-4i are associated with reduced dementia risk via unknown mechanisms. To examine vildagliptin (DPP-4i) effects on the intestinal microbiota in T2D patients, plasma metab...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
ff58888b-07dd-5072-a90a-976648d17122
DOI
10.21203/rs.3.rs-6596504/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Vildagliptin modulates the microbiota and induces an immunometabolic neuroprotective profile in type 2 diabetesDOI 10.21203/rs.3.rs-6596504/v1
Select a neighboring publication to make it the new centre.